EX-10.12 12 d547651dex1012.htm EX-10.12 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406...Api Supply Agreement • May 5th, 2020 • New York
This API Supply Agreement (“Agreement”) is made as of the January I, 2018 (“Effective Date”), by and between Xeris Pharmaceuticals, Inc., a Delaware Corporation, with a place of business at 180 N. LaSalle Street, Suite 1800, Chicago, Illinois 60601, USA (“XERIS”). and Bachem Americas, Inc., a California Corporation, with a place of business at 3132 Kashiwa Street, Torrance, CA 90505, USA (“BACHEM”). XERIS and BACHEM may be referred to individually as a “Party” or collectively as the “Parties.”
EX-10.7 11 filename11.htm PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS....Api Supply Agreement • May 5th, 2020 • New York
This API SUPPLY AGREEMENT (this “Supply Agreement” or this “Agreement”), dated as of September 11, 2013 (the “Supply Agreement Effective Date”), is by and between Pfizer Inc. (“Pfizer”), organized and existing under the laws of Delaware and doing business at 235 East 42nd Street, New York, NY 10017 and CLARUS THERAPEUTICS, INC., a corporation with offices at 555 SKOKIE BLVD., SUITE 340, NORTHBROOK, IL 60062 (“Customer”).
ContractApi Supply Agreement • May 5th, 2020 • California
EX-10.2 3 moehsex102.htm EXHIBIT 10.2 Exhibit 10.2 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL AMENDED AND RESTATED API SUPPLY AGREEMENT This Amended and Restated API Supply Agreement (this “Agreement”) is effective as of July 07, 2009 (the “Effective Date”) and amended and restated as of Oct 2, 2017 (“Restatement Date”) by and between Adamas Pharma, LLC, with an address of 1900 Powell St., Suite 750, Emeryville, CA 94608 USA (“Company”), and Moehs Ibérica, S.L., a Spanish corporation, having its principal place of business at Poligono Industrial Rubi Sud - C/ Cesar, Martinell i Brunet 12A, 08191 Rubi, Barcelona, Spain (“Manufacturer”). Company and Manufacturer may be referred to individually as a “Party” or collectively as “Parties.” RECITALS WHEREAS, Company is engaged in th
EX-10.72 3 dex1072.htm API SUPPLY AGREEMENT DATED DECEMBER 17, 2008 [ * ] = Certain information on this document has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect...Api Supply Agreement • May 5th, 2020 • New York
This API Supply Agreement (this “Agreement”), is made and executed as of this 17th day of December, 2008 (the “Effective Date”), by and among:
API SUPPLY AGREEMENTApi Supply Agreement • November 30th, 2017
EX-10.6 9 a04-6330_1ex10d6.htm EX-10.6 API SUPPLY AGREEMENTApi Supply Agreement • May 5th, 2020 • Illinois
This API Supply Agreement (this “Agreement”), dated as of April 16, 2004 and effective as of May 1, 2004 (the “Effective Date”), is by and between Hospira, Inc., a Delaware corporation (“Hospira”), and Abbott Laboratories, an Illinois corporation (“Abbott”).
EX-10.162 6 dex10162.htm API SUPPLY AGREEMENT CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION Execution Copy API SUPPLY AGREEMENTApi Supply Agreement • May 5th, 2020 • New York
This API Supply Agreement (this “Agreement”) is made as of this 22nd day of November, 2006 (“Effective Date”), by and between INDEVUS PHARMACEUTICALS INC., a corporation organized and existing under the laws of the State of Delaware, United States of America, and having an office at 33 Hayden Avenue, Lexington, MA 02421-7971, United States (“Indevus”) and HELSINN CHEMICALS SA and HELSINN ADVANCED SYNTHESIS SA, both corporations organized and existing under the law of Switzerland and having their registered office at Via Industria 24, 6710 Biasca, Switzerland (“Helsinn”). Indevus and Helsinn hereinafter are collectively referred to as the “Parties” and individually as a “Party”.
EX-10.3 7 d605505dex103.htm EX-10.3 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Execution...Api Supply Agreement • May 5th, 2020
This API Supply Agreement (the “Agreement”) is entered into this 22nd day of August, 2008 (the “Effective Date”), by and among Recro Pharma, Inc., a company incorporated under the laws of the Commonwealth of Pennsylvania (“Customer” or “Recro”), and Orion Corporation, a company incorporated under the laws of Finland (“Supplier” or “Orion”). Customer and Supplier may each be referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
EX-10.1 2 dex101.htm API SUPPLY AGREEMENT CONFIDENTIAL CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE...Api Supply Agreement • May 5th, 2020 • New York
THIS API SUPPLY AGREEMENT (this “Agreement”) is entered into and dated as of the 25th day of May, 2011 (the “Effective Date”) by and between Amarin Pharmaceuticals Ireland Ltd., a corporation organized under the laws of Ireland and having its principal office at First Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge, Dublin 4, Ireland (“Amarin”), and Equateq Limited, a company incorporated in England with registered number [5507387] and with its registered office at Lion House, Red Lion Street, London, WC1R 4GB but with its principal offices at Callanish, Isle of Lewis, HS2 9ED (“Equateq”). Amarin and Equateq are sometimes referred to herein individually as a “Party” and collectively as “Parties.”
API Supply AgreementApi Supply Agreement • January 25th, 2021 • Emmaus Life Sciences, Inc. • Pharmaceutical preparations • California
This Agreement (this “Agreement”), is made and entered into this _16__ day of 6_, 2017 (the “Effective Date”) by and between Emmaus Life Sciences, Inc., a Delaware corporation with offices at 21250 Hawthorne Blvd., Suite 800, Torrance, California 90503, the United States of America (hereinafter called "Manufacturer") and Telcon Inc., Korea corporation ("Supplier"), with offices at 684, Dongtangiheung-ro, Giheung-gu, Yongin-si, Gyeonggi-do.
IN WITNESS THEREOF, each of Xeris and Bachem have caused this Third Amendment to be executed by their respective duly authorized representatives as of the Third Amendment Effective Date. Xeris Pharmaceuticals, Inc. By: /s/ Peter Valentinsson Name:...Api Supply Agreement • November 8th, 2024 • Xeris Biopharma Holdings, Inc. • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED API SUPPLY AGREEMENTApi Supply Agreement • August 6th, 2021 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This API Supply Agreement (“Agreement”) is made as of July 13, 2021 (the “Effective Date”), by and between Supernus Pharmaceuticals, Inc., a Delaware Corporation, with a place of business at 9715 Key West Avenue, Rockville Maryland, USA (“Supernus”) and Bachem Americas, Inc., a California Corporation, with a place of business at 3132 Kashiwa Street, Torrance, CA 90505, USA, and its Affiliates (“Bachem”). Supernus and Bachem may be referred to individually as a “Party” or collectively as the “Parties.”
SECOND AMENDMENT TO API SUPPLY AGREEMENTApi Supply Agreement • May 8th, 2012 • Amarin Corp Plc\uk • Pharmaceutical preparations
This SECOND AMENDMENT TO API SUPPLY AGREEMENT (the “Second Amendment”) is made as of this 9th day of January, 2012 (the “Second Amendment Effective Date”), by and between Amarin Pharmaceuticals Ireland Ltd., a corporation organized under the laws of Ireland and having its principal office at First Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge, Dublin 4, Ireland (“Amarin”), and Equateq Limited, a company incorporated in England with registered number 5507387 and with its registered office at Lion House, Red Lion Street, London, WC1R 4GB but with its principal offices at Callanish, Isle of Lewis, HS2 9ED (“Equateq”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED SECOND AMENDMENT TO API SUPPLY...Api Supply Agreement • August 10th, 2022 • Xeris Biopharma Holdings, Inc. • Pharmaceutical preparations • New York
This Second Amendment (“Second Amendment”) is entered into as of May 2, 2022 (the “Second Amendment Effective Date”), by and between Xeris Pharmaceuticals, Inc. (“Xeris”) and Bachem Americas, Inc. (“Bachem”). Xeris and Bachem may be referred to individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Second Amendment without definition shall have the same meaning as set forth in the Agreement (defined below).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. API SUPPLY AGREEMENTApi Supply Agreement • March 12th, 2019 • Nabriva Therapeutics PLC • Pharmaceutical preparations • England and Wales
THIS ACTIVE PHARMACEUTICAL INGREDIENT SUPPLY AGREEMENT (this “Agreement”) is made as of this 23rd day of November 2018 (“Effective Date”), by and between NABRIVA THERAPEUTICS IRELAND DAC (“NABRIVA”), with a principal place of business at Suite 510, Regus Dublin Airport, Skybridge House Dublin Airport, Swords, County Dublin, Ireland and HOVIONE LIMITED (“HOVIONE”), with a principal place of business at Loughbeg, Ringaskiddy, Co. Cork, Ireland. NABRIVA and HOVIONE shall be individually referred to as a “Party” and collectively referred to as the “Parties.”
API SUPPLY AGREEMENTApi Supply Agreement • November 7th, 2016 • Horizon Pharma PLC • Pharmaceutical preparations • New York
This API Supply Agreement (“Agreement”) is made as of the 3rd day of November, 2010 (“Effective Date”), by and between Raptor Therapeutics, Inc., a Delaware Corporation, with a place of business at 9 Commercial Boulevard, Suite 200, Novato, California 94949, U.S.A. (“RAPTOR”), and Cambrex Profarmaco Milano, Via Cucchiari 17, 20155 Milan, Italy (“CAMBREX”). RAPTOR and CAMBREX may be referred to individually as a “Party” or collectively as the “Parties.”
AMENDMENT TO API SUPPLY AGREEMENTApi Supply Agreement • February 29th, 2012 • Amarin Corp Plc\uk • Pharmaceutical preparations
This AMENDMENT TO API SUPPLY AGREEMENT (the “Amendment”) is made as of this 19th day of October, 2011 (the “Amendment Effective Date”), by and between Amarin Pharmaceuticals Ireland Ltd., a corporation organized under the laws of Ireland and having its principal office at First Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge, Dublin 4, Ireland (“Amarin”), and Equateq Limited, a company incorporated in England with registered number 5507387 and with its registered office at Lion House, Red Lion Street, London, WC1R 4GB but with its principal offices at Callanish, Isle of Lewis, HS2 9ED (“Equateq”).
API SUPPLY AGREEMENTApi Supply Agreement • March 12th, 2021
These terms are a legal agreement (“Agreement”) between OpenAustralia Foundation. (“OpenAustralia”) and You for the use of the PlanningAlerts commercial API access services. By using the PlanningAlerts commercial API access services, You accept these terms. If You do not accept them, do not use the PlanningAlerts commercial API access services. You are bound by these terms even if You do not read all the terms. These terms replace all previous terms.
API SUPPLY AGREEMENTApi Supply Agreement • November 2nd, 2020 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations • New York
This API Supply Agreement (“Agreement”) is made as of the 3rd day of November, 2010 (“Effective Date”), by and between Raptor Therapeutics, Inc., a Delaware Corporation, with a place of business at 9 Commercial Boulevard, Suite 200, Novato, California 94949, U.S.A. (“RAPTOR”), and Cambrex Profarmaco Milano, Via Cucchiari 17, 20155 Milan, Italy (“CAMBREX”). RAPTOR and CAMBREX may be referred to individually as a “Party” or collectively as the “Parties.”
THIRD AMENDMENT TO API SUPPLY AGREEMENTApi Supply Agreement • May 8th, 2012 • Amarin Corp Plc\uk • Pharmaceutical preparations
This THIRD AMENDMENT TO API SUPPLY AGREEMENT (the “Third Amendment”) is made as of this 7th day of May, 2012 (the “Third Amendment Effective Date”), by and between Amarin Pharmaceuticals Ireland Ltd., a corporation organized under the laws of Ireland and having its principal office at First Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge, Dublin 4, Ireland (“Amarin”), and Equateq Limited, a company incorporated in England with registered number 5507387 and with its registered office at Lion House, Red Lion Street, London, WC1R 4GB but with its principal offices at Callanish, Isle of Lewis, HS2 9ED (“Equateq”).
API SUPPLY AGREEMENTApi Supply Agreement • November 23rd, 2010 • Raptor Pharmaceutical Corp • Pharmaceutical preparations • New York
This API Supply Agreement (“Agreement”) is made as of the 15th day of November, 2010 (“Effective Date”), by and between Raptor Therapeutics, Inc., a Delaware Corporation, with a place of business at 9 Commercial Boulevard, Suite 200, Novato, California 94949, U.S.A. (“RAPTOR”), and Cambrex Profarmaco Milano, Via Cucchiari 17, 20155 Milan, Italy (“CAMBREX”). RAPTOR and CAMBREX may be referred to individually as a “Party” or collectively as the “Parties.”
API SUPPLY AGREEMENTApi Supply Agreement • August 6th, 2024
These terms are a legal agreement (“Agreement”) between OpenAustralia Foundation. (“OpenAustralia”) and You for the use of the Planning Alerts commercial API access
API SUPPLY AGREEMENTApi Supply Agreement • January 1st, 2022
These terms are a legal agreement (“Agreement”) between OpenAustralia Foundation. (“OpenAustralia”) and You for the use of the PlanningAlerts commercial API access services. By using the PlanningAlerts commercial API access services, You accept these terms. If You do not accept them, do not use the PlanningAlerts commercial API access services. You are bound by these terms even if You do not read all the terms. These terms replace all previous terms.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT to API...Api Supply Agreement • August 5th, 2021 • Nabriva Therapeutics PLC • Pharmaceutical preparations
THIS FIRST AMENDMENT (“Amendment”) is entered into by and between Nabriva Therapeutics Ireland DAC, with a principal place of business at Suite 510, Regus Dublin Airport, Skybridge House Dublin Airport, Swords, County Dublin, Ireland (“Nabriva”), and Hovione Limited, (“Hovione”). All capitalized terms not defined in this Amendment shall have the same meaning as set forth in the Agreement (defined below).
Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. GENERIC API SUPPLY AGREEMENTApi Supply Agreement • March 29th, 2023 • Avadel Pharmaceuticals PLC • Pharmaceutical preparations • Delaware
This GENERIC API SUPPLY AGREEMENT (“Agreement”) is made this 2nd day of January 2020 (“Effective Date”) by and between Euticals Inc. (“Supplier”), with a place of business at 2460 W. Bennett Street, Springfield, MO 65807 and Avadel CNS Pharmaceuticals, LLC (“Customer”), with a place of business at 16640 Chesterfield Grove Road, Suite 200, Chesterfield, MO 63005. Supplier and Customer may be referred to herein as a “Party” or “Parties” as the context requires.
FIRST AMENDMENT TO API SUPPLY AGREEMENTApi Supply Agreement • May 13th, 2021 • Xeris Pharmaceuticals Inc • Pharmaceutical preparations • New York
This first Amendment (“First Amendment”) is entered into as of February 26, 2021 (the “First Amendment Effective Date”), by and between Xeris Pharmaceuticals, Inc. (“Xeris”) and Bachem Americas, Inc. (“Bachem”). Xeris and Bachem may be referred to individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this First Amendment without definition shall have the same meaning as set forth in the Agreement (defined below).
THIRD AMENDMENT to API SUPPLY AGREEMENTApi Supply Agreement • April 17th, 2023 • Nabriva Therapeutics PLC • Pharmaceutical preparations
THIS THIRD AMENDMENT (“Amendment”) is entered into by and between Nabriva Therapeutics Ireland DAC, with a principal place of business at Alexandra House, Office 225/227, The Sweepstakes, Ballsbridge, Dublin 4, D04 C7H2, Ireland (“Nabriva”), and Hovione Limited, (“Hovione”). All capitalized terms not defined in this Amendment shall have the same meaning as set forth in the Agreement (defined below).
API SUPPLY AGREEMENTApi Supply Agreement • March 9th, 2024
These terms are a legal agreement (“Agreement”) between OpenAustralia Foundation. (“OpenAustralia”) and You for the use of the PlanningAlerts commercial API access
DEXMEDETOMIDINE API SUPPLY AGREEMENTApi Supply Agreement • October 22nd, 2019 • Baudax Bio, Inc. • Services-misc health & allied services, nec
This API Supply Agreement (the “Agreement”) is entered into this 22nd day of August, 2008 (the “Effective Date”), by and among Recro Pharma, Inc., a company incorporated under the laws of the Commonwealth of Pennsylvania (“Customer” or “Recro”), and Orion Corporation, a company incorporated under the laws of Finland (“Supplier” or “Orion”). Customer and Supplier may each be referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
ContractApi Supply Agreement • May 5th, 2020 • New York
EX-10.54 3 cambrexagreement.htm CAMBREX API AGREEMENT Exhibit 10.54 EXECUTION COPY API SUPPLY AGREEMENT This API Supply Agreement (“Agreement”) is made as of the 15th day of November, 2010 (“Effective Date”), by and between Raptor Therapeutics, Inc., a Delaware Corporation, with a place of business at 9 Commercial Boulevard, Suite 200, Novato, California 94949, U.S.A. (“RAPTOR”), and Cambrex Profarmaco Milano, Via Cucchiari 17, 20155 Milan, Italy (“CAMBREX”). RAPTOR and CAMBREX may be referred to individually as a “Party” or collectively as the “Parties.” Background RAPTOR is engaged in the business of developing and commercializing therapeutic products through the application of specialized drug targeting platforms and formulation expertise for under-served patient populations; CAMBREX is engaged in the manufacture and supply of active pharmaceutical ingredients for research and development purposes and/or commercial use; RAPTOR desires to purchase from CAMBREX, and CAMBREX desires to
API SUPPLY AGREEMENTApi Supply Agreement • December 12th, 2017
